Viracta Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VIRX Nasdaq 8731 https://www.viracta.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Viracta Therapeutics Inc

Viracta Therapeutics to Present at the Jefferies Healthcare Conference - May 31st, 2023 8:15 pm
2 “Strong Buy” Penny Stocks With Over 400% Upside on the Horizon - May 17th, 2023 1:50 pm
Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference - May 11th, 2023 8:05 pm
Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates - May 8th, 2023 8:05 pm
Viracta Therapeutics Announces Departure of Chief Medical Officer - May 2nd, 2023 8:05 pm
Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days - Apr 19th, 2023 8:30 pm
Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update - Mar 13th, 2023 8:05 pm
Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference - Mar 8th, 2023 9:05 pm
Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference - Feb 7th, 2023 9:05 pm
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma - Jan 19th, 2023 1:30 pm
Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives - Jan 8th, 2023 6:00 pm
Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress - Nov 30th, 2022 11:10 pm
Viracta Therapeutics Announces New Employment Inducement Grant - Nov 21st, 2022 10:08 pm
Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs - Nov 10th, 2022 9:05 pm
Viracta Therapeutics to Present at Upcoming Investor Conferences - Nov 2nd, 2022 8:05 pm
Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth - Sep 19th, 2022 12:00 pm
Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma - Sep 7th, 2022 1:00 pm
Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases - Aug 16th, 2022 8:15 pm
Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors - Aug 11th, 2022 1:00 pm
Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates - Aug 9th, 2022 12:30 pm